Validation of Residual Cancer Burden as Prognostic Factor for Breast Cancer Patients After Neoadjuvant Therapy

BACKGROUND: Assessing the residual cancer burden (RCB) predictive performance, the potential subgroup effects, and time-dependent impact on breast cancer patients who underwent neoadjuvant therapy in a developer’s independent cohort is essential for its usage in clinical routine. METHODS: Between 20...

Descripción completa

Detalles Bibliográficos
Autores principales: Müller, Hannah Deborah, Posch, Florian, Suppan, Christoph, Bargfrieder, Ute, Gumpoldsberger, Melanie, Hammer, Robert, Hauser, Hubert, Dandachi, Nadia, Prein, Kurt, Stoeger, Herbert, Lax, Sigurd, Balic, Marija
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Breast Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6864028/
https://www.ncbi.nlm.nih.gov/pubmed/31452052
http://dx.doi.org/10.1245/s10434-019-07741-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6864028/
https://www.ncbi.nlm.nih.gov/pubmed/31452052
http://dx.doi.org/10.1245/s10434-019-07741-w

Ejemplares similares